EcoDrugPlus

Tyrosine Hydroxylase

Ensembl ID : ENSNSUG00000017446
Gene Symbol: TH
3 Cross references
187 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Tyrosine Kinase 2

Ensembl ID : ENSNSUG00000003024
Gene Symbol: TYK2
3 Cross references
195 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Tyrosine-Protein Kinase Receptor Ufo-Like

Ensembl ID : ENSNSUG00000006387
Gene Symbol: LOC113428203
2 Cross references
195 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Tyrosine-Protein Kinase Receptor Ufo-Like

Ensembl ID : ENSNSUG00000006558
Gene Symbol: LOC113428211
2 Cross references
195 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Tyrosine-Protein Kinase Receptor Ufo-Like

Ensembl ID : ENSNSUG00000006555
Gene Symbol: LOC113428209
2 Cross references
195 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Utrophin

Ensembl ID : ENSNSUG00000010401
Gene Symbol: UTRN
3 Cross references
252 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Vascular Endothelial Growth Factor A

Ensembl ID : ENSNSUG00000008566
Gene Symbol: VEGFA
1 Cross references
253 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Venom Prothrombin Activator Notecarin-D1

Ensembl ID : ENSNSUG00000011294
Gene Symbol: LOC113428980
2 Cross references
235 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Vitamin D Receptor

Ensembl ID : ENSNSUG00000003057
Gene Symbol: VDR
3 Cross references
459 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Vitamin K Epoxide Reductase Complex Subunit 1

Ensembl ID : ENSNSUG00000011100
Gene Symbol: VKORC1
3 Cross references
189 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Voltage-Dependent L-Type Calcium Channel Subunit Alpha-1s-Like

Ensembl ID : ENSNSUG00000001097
Gene Symbol: LOC113418965
2 Cross references
258 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Voltage-Dependent L-Type Calcium Channel Subunit Alpha-1s-Like

Ensembl ID : ENSNSUG00000014595
Gene Symbol: LOC113418846
2 Cross references
258 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Select Keywords:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).